Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 15 IN PLASTIC CONTAINER.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 mL/kg/hr initially, titrate up to 100-125 mL/hr. Do not exceed 125 mL/hr.
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day, administered at a rate of 200 mL/hour, adjusted based on metabolic and fluid needs.
None Documented
None Documented
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution